1.Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori KOGA ; Hideki IWAMOTO ; Hiroyuki SUZUKI ; Shigeo SHIMOSE ; Masahito NAKANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2023;29(2):242-251
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.
2.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
3.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
4.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
5.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
6.Recommendations for Conducting Post-Marketing Database Study in Japan Based on the Critical Appraisal of Published Articles from Overseas Real-World Data (RWD) Analyses
Shinichi MATSUDA ; Nobuyuki FUKADA ; Masahito OISHI ; Hiroaki OKA ; Ryousuke HARA ; Ai KOJIMA ; Shun NAKANO ; Katsuaki MOTOYOSHI ; Shigeki IGARASHI ; Yuko SASAKI ; Natsuko KAMEYAMA ; Kazuhiro KUBOTA
Japanese Journal of Pharmacoepidemiology 2021;26(1):41-54
Real-world data (RWD), such as a health insurance claim database and electronic medical record database, which records daily medical care information, is one of the most important data sources in pharmacoepidemiological studies. In Japan, a post-marketing database study has been added as a new category of post-marketing surveillance since April 2018. It is expected that the post-marketing database studies will be conducted in the actual risk management plan; however, at this point, few have reached the stage of publishing study results. On the other hand, overseas, many database research results using RWD have already been reported. Although it is necessary to keep in mind that there are differences in the characteristics of the databases (e.g., data contents, structures) and the differences in the medical environment between overseas and Japan, we think that critically reviewing these reports has a reference value for the planning, execution, and interpretation of the results in performing post-marketing database studies in Japan. The purpose of this report is to examine the characteristics and cautions of the database studies through a critical review of published articles of overseas RWD studies and to make recommendations that are useful for conducting post-marketing database studies in Japan. We hope this article will become a help in the planning and implementation of future post-marketing database studies.